title: AME position statement: primary hyperparathyroidism in clinical practice.
authors: Endocrine Unit, Arcispedale S. Maria Nuova IRCCS, Reggio Emilia, Italy.
authors: Michele
authors: M
authors: Zini
authors: Roberto
authors: R
authors: Attanasio
authors: Roberto
authors: R
authors: Cesareo
authors: Ignazio
authors: I
authors: Emmolo
authors: Andrea
authors: A
authors: Frasoldati
authors: Laura
authors: L
authors: Gianotti
authors: Rinaldo
authors: R
authors: Guglielmi
authors: Alessandro
authors: A
authors: Piovesan
authors: Massimo
authors: M
authors: Procopio
authors: Alfredo
authors: A
authors: Scillitani
authors: Annibale
authors: A
authors: Versari
authors: Jens
authors: J
authors: Bollerslev
authors: Dhanwada Sudhaker
authors: DS
authors: Rao
authors: Claudio
authors: C
authors: Marcocci
authors: Giorgio
authors: G
authors: Borretta
mesh_terms: D050071:Bone Density Conservation Agents / Q000627:therapeutic use; D001847:Bone Diseases / Q000209:etiology; D057966:Calcimimetic Agents / Q000627:therapeutic use; D004164:Diphosphonates / Q000627:therapeutic use; D005260:Female; D006801:Humans; D049950:Hyperparathyroidism, Primary / Q000150:complications / Q000175:diagnosis* / Q000188:drug therapy / Q000601:surgery; D007674:Kidney Diseases / Q000209:etiology; D008297:Male; D010281:Parathyroid Hormone / Q000097:blood; D016105:Parathyroidectomy; D012720:Severity of Illness Index
chemical_list: D050071:Bone Density Conservation Agents; D057966:Calcimimetic Agents; D004164:Diphosphonates; D010281:Parathyroid Hormone